BDSI - BioDelivery Sciences posts a record gain after favorable court ruling

BioDelivery Sciences (BDSI +25.4%) has added over a quarter of value to record its best intraday gain since early 2014 after a court ruling upheld the validity of two of the patents linked to the company’s FDA-approved pain killer Belbuca. The decision issued by a trial judge in Delaware reaffirms the patents 8,147,866 and 9,901,539, which expire in 2027 and 2032, respectively, and prevents Alvogen from selling a generic version of the Belbuca for a decade, Bloomberg reports. District Judge Colm Connolly determined that in addition to some claims related to the patent 8,147,866, those on a third patent 9,655,843 ending in 2027 were invalid. During the first nine months of the year, Belbuca generated $109.8M net sales for BioDelivery (NASDAQ:BDSI), making up 90% of its total net product sales. Last month, Seeking Alpha contributor Avisol Capital Partners saw the weakness in BioDelivery (BDSI) shares as an opportunity subject to a favorable outcome

For further details see:

BioDelivery Sciences posts a record gain after favorable court ruling